Substituted tricyclics

US6713645B1 · kind B1 · utility

Assignee

• ELI LILLY AND COMPANY · US

Inventors

• Nicholas J. Bach · Indianapolis, US
• Susan E. Draheim · Indianapolis, US
• Robert D. Dillard · Zionsville, US
• Edward David Mihelich · Carmel, US
• Jason Scott Sawyer · Indianapolis, US
• Douglas Wade Beight · Frankfort, US
• Michael LeRoy Phillips · Indianapolis, US
• Tulio Suarez · Indianapolis, US
• Daniel Jon Sall · Greenwood, US
• Jolie Anne Bastian · Indianapolis, US
• Michael Lyle Denney · Franklin, US
• Gary Alan Hite · Indianapolis, US
• Michael Dean Kinnick · Indianapolis, US
• Robert Theodore Vasileff · Indianapolis, US
• John Michael Morin, Jr. · Brownsburg, US
• Ho-Shen Lin · Indianapolis, US
• Michael Enrico Richett · Indianapolis, US
• Richard Waltz Harper · Indianapolis, US
• John McNeill McGill · Lafayette, US
• Benjamin Alan Anderson · Zionsville, US
• Nancy Kay Harn · Indianapolis, US
• Richard James Loncharich · Carmel, US
• Richard W. Schevitz · Indianapolis, US

Key dates

• Filing date: Oct 13, 2000
• Grant date: Mar 30, 2004
• Expiry date: Nov 15, 2021

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07F9/5728
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

A class of novel tricyclics is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of conditions such as septic shock.